Tatva Chintan Pharma Chem Limited (IN:TATVA)
:TATVA
Want to see IN:TATVA full AI Analyst Report?
Top Page
Tatva Chintan Pharma Chem Limited
(TATVA)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹1,180.00
▼(-15.01% Downside)
Action:Reiterated
Date:05/22/26
The score is primarily held back by weak cash-flow quality (negative free cash flow) and volatile profitability, despite a solid balance-sheet position. Technicals are also weak with the stock trading below major moving averages and subdued momentum. Valuation is a further headwind due to the high P/E and minimal dividend yield.
Positive Factors
Balance Sheet Strength
Low reported leverage (7.82B equity vs 1.20B debt) provides durable financial flexibility. This cushioning supports funding working-capital swings, customer qualification capex and temporary earnings volatility without immediate solvency pressure, enabling strategic investments.
Negative Factors
Weak Cash Generation
Consistent negative free cash flow indicates working-capital strain and/or heavy reinvestment needs. This raises funding risk, heightens reliance on the balance sheet or external financing, and constrains the company’s ability to self-fund growth, dividends or de-risk operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Low reported leverage (7.82B equity vs 1.20B debt) provides durable financial flexibility. This cushioning supports funding working-capital swings, customer qualification capex and temporary earnings volatility without immediate solvency pressure, enabling strategic investments.
Read all positive factors
Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹28.00B
Dividend Yield0.07%
Average Volume (3M)12.52K
Price to Earnings (P/E)66.6
Beta (1Y)1.11
Revenue Growth32.18%
EPS Growth636.02%
CountryIN
Employees689
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)7.58
Shares Outstanding23,392,056
10 Day Avg. Volume25,333
30 Day Avg. Volume12,516
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.15
Price to Sales (P/S)4.87
P/FCF Ratio-29.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27
Revenue Forecast (FY)₹6.21B
Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model
Company Description
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for ...
How the Company Makes Money
Tatva Chintan primarily makes money by manufacturing and selling specialty chemicals to industrial customers. Its revenue model is product-sales driven: customers (typically chemical, pharmaceutical, agrochemical, and battery-material manufacturer...
Tatva Chintan Pharma Chem Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
77
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.34B | 5.06B | 3.83B | 3.94B | 4.24B | 4.34B |
| Gross Profit | 2.22B | 1.82B | 1.84B | 2.11B | 1.91B | 2.32B |
| EBITDA | 567.40M | 931.58M | 342.13M | 689.34M | 676.30M | 1.08B |
| Net Income | 177.36M | 420.54M | 57.13M | 303.54M | 454.87M | 958.74M |
Balance Sheet | ||||||
| Total Assets | 9.08B | 10.04B | 8.36B | 8.19B | 7.56B | 6.58B |
| Cash, Cash Equivalents and Short-Term Investments | 178.47M | 87.91M | 117.01M | 456.68M | 412.15M | 638.19M |
| Total Debt | 830.13M | 1.20B | 363.88M | 142.71M | 1.70B | 1.20B |
| Total Liabilities | 1.53B | 2.22B | 974.25M | 816.36M | 2.42B | 1.85B |
| Stockholders Equity | 7.54B | 7.82B | 7.39B | 7.37B | 5.15B | 4.73B |
Cash Flow | ||||||
| Free Cash Flow | -426.18M | -841.44M | -516.01M | -304.71M | -1.75B | -687.79M |
| Operating Cash Flow | 133.81M | 296.30M | 246.71M | 980.44M | 277.83M | 203.78M |
| Investing Cash Flow | -577.76M | -1.17B | -652.54M | -1.21B | -1.01B | -1.97B |
| Financing Cash Flow | 457.32M | 816.19M | 165.66M | 305.19M | 377.95M | 2.35B |
Tatva Chintan Pharma Chem Limited Technical Analysis
Positive
1388.35
Price Trends
1237.62
Negative
1206.72
Negative
1243.74
Negative
Market Momentum
-14.55
Negative
49.73
Neutral
71.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Positive. The current price of 1388.35 is above the 20-day moving average (MA) of 1176.32, above the 50-day MA of 1237.62, and above the 200-day MA of 1243.74, indicating a neutral trend. The MACD of -14.55 indicates Negative momentum. The RSI at 49.73 is Neutral, neither overbought nor oversold. The STOCH value of 71.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TATVA.
Tatva Chintan Pharma Chem Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹91.72B | 50.90 | ― | 0.62% | -2.29% | -3.26% | |
67 Neutral | ₹135.76B | 30.56 | ― | 0.48% | -0.95% | 9.51% | |
64 Neutral | ₹29.55B | 19.81 | ― | 0.09% | 15.19% | 9.27% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | ₹102.76B | 36.73 | ― | 0.74% | 5.04% | 11.10% | |
49 Neutral | ₹28.00B | 66.57 | ― | 0.07% | 32.18% | 636.02% | |
45 Neutral | ₹176.32B | 41.97 | ― | 0.26% | 14.15% | 26.69% |
* Basic Materials Sector Average
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,197.15
281.46
30.74%
IN:AARTIIND
AARTI Industries Ltd
486.20
46.07
10.47%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,793.40
-265.61
-12.90%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
645.15
-50.93
-7.32%
IN:ROSSARI
Rossari Biotech Ltd
533.40
-136.75
-20.41%
IN:VINATIORGA
Vinati Organics Limited
1,309.60
-582.75
-30.80%
Tatva Chintan Pharma Chem Limited Corporate Events
Tatva Chintan Plans Virtual Investor Meeting With OysterRock Capital
Mar 19, 2026
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one investor meeting with OysterRock Capital on 24 March 2026, as disclosed under SEBI’s listing obligations framework. The company emphasized that only publicly available info...
Tatva Chintan Faces New Gas Supply Curbs and Pricing Regime Under Government Order
Mar 14, 2026
Tatva Chintan Pharma Chem has disclosed that its natural gas supply will be regulated under the Government of India’s new Natural Gas (Supply Regulation) Order, 2026, issued in response to Middle East geopolitical disruptions. Industrial gas...
Tatva Chintan Schedules Compliant Virtual Investor Meet on 16 March 2026
Mar 11, 2026
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one investor meeting with Ask Wealth Advisor Private Limited on 16 March 2026, in line with market disclosure norms under SEBI’s Listing Obligations and Disclosure Requirements...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.